Finasteride and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Finasteride and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Finasteride and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Finasteride

5-Alpha Reductase Inhibitor | DHT Blocker for Hair Loss & BPH

Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT).

Half-life: 6-8 hours (DHT suppression persists ~24 hours) Typical dose: 1mg/day (hair loss) or 5mg/day (BPH) hair loss
5 alpha reductase estrogenichepatotoxicteratogenic
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Skin
low

Shared Safety Flags

2x 2 estrogenic compounds (Finasteride, LGD-4033). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 hepatotoxic compounds (Finasteride, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Finasteride, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Finasteride with LGD-4033?

Combining Finasteride with LGD-4033 is not recommended. Both Finasteride and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Finasteride and LGD-4033 safe together?

This combination carries significant risk. Both Finasteride and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Finasteride and LGD-4033?

Both Finasteride and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Finasteride and LGD-4033?

Finasteride has a half-life of 6-8 hours (DHT suppression persists ~24 hours) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Finasteride vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.